Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5821-5830 Newer>

The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool August 11, 2009 Brian Orelli	A Drug Stock IPO! Finally! Today's offering, Cumberland Pharmaceuticals is in a special breed of small drugmakers: it's actually profitable.
The Motley Fool August 10, 2009 Rich Smith	This Just In: Upgrades and Downgrades Goldman hearts Merck. Should you?
The Motley Fool August 10, 2009 Brian Orelli	This Volatile Stock Has Growth Potential China is scary. AOB? Scarier.
Insurance & Technology August 4, 2009 John Reynolds	Electronic Health Records: A Place to Start, Not a Destination End-game electronic health record solutions need to focus on integrating individuals' health with wealth and making it personal and actionable in a consumer-directed healthcare world.
HBS Working Knowledge August 7, 2009 Jim Heskett	Why Can't Americans Get Health Care Right? It is said that health care is the biggest threat to the long-term health of the U.S. economy and therefore, to some extent, the global economy.
The Motley Fool August 7, 2009 Chris Jones	Thoratec Isn't Heartbroken Although the therapeutic device maker recently dropped its takeover bid for HeartWare International in the face of a challenge from the FTC, strength in Thoratec's cardiovascular division drove solid revenue growth.
The Motley Fool August 7, 2009 Brian Orelli	A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court.
The Motley Fool August 5, 2009 Brian Orelli	The Cash Cow Is Out of Milk ViroPharma has milked its antibiotic Vancocin, which it bought from Eli Lilly in 2004, pretty well, but it looks like the cash cow is finally running dry.
The Motley Fool August 5, 2009 Brian Orelli	Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data.
<Older 5821-5830 Newer> Return to current articles.